Nivolumab and Ipilimumab +/-UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

被引：0
|
作者：
Haakensen, V. [1 ]
Nowak, A. [2 ]
Ellingsen, E. [3 ]
Grundberg, O. [4 ]
Farooqi, S. [1 ]
Mcculloch, T. [5 ]
Cedres, S. [6 ]
Bjaanaes, M. [1 ]
Helland, A. [7 ,8 ]
机构：
[1] Oslo Univ Hosp, Div Canc Med, Oslo, Norway
[2] Univ Western Australia, Natl Ctr Asbestos Related Dis, Crawley, ACT, Australia
[3] Ultimovacs Asa, Oslo, Norway
[4] Karolinska Inst, Stockholm, Sweden
[5] Aalborg Univ Hosp, Aalborg, Denmark
[6] Vall Dhebron Inst Oncol Vhio, Med Oncol, Vall Dhebron Barcelona Hosp Campus, Barcelona, Spain
[7] Univ Oslo, Clin Med, Oslo, Norway
[8] Oslo Univ Hosp, Oslo, Norway
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Immunotherapy; Mesothelioma; clinical trial;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P24.07
引用
收藏
页码：S380 / S380
页数：1
相关论文
共 21 条
  • [1] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    Vilde Drageset Haakensen
    Anna K. Nowak
    Espen Basmo Ellingsen
    Saima Jamil Farooqi
    Maria Moksnes Bjaanæs
    Henrik Horndalsveen
    Tine Mcculloch
    Oscar Grundberg
    Susana M. Cedres
    Åslaug Helland
    Journal of Translational Medicine, 19
  • [2] NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
    Haakensen, Vilde Drageset
    Nowak, Anna K.
    Ellingsen, Espen Basmo
    Farooqi, Saima Jamil
    Bjaanaes, Maria Moksnes
    Horndalsveen, Henrik
    Mcculloch, Tine
    Grundberg, Oscar
    Cedres, Susana M.
    Helland, Aslaug
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [3] UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
    Haakensen, Vilde Drageset
    Ojlert, Asa Kristina
    Thunold, Solfrid
    Farooqi, Saima
    Nowak, Anna K.
    Chin, Wee L.
    Grundberg, Oscar
    Szejniuk, Weronika Maria
    Cedres, Susana
    Sorensen, Jens Benn
    Dalen, Tonje Sofie
    Lund-Iversen, Marius
    Bjaanaes, Maria
    Helland, Aslaug
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [4] Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study
    Disselhorst, M.
    Harms, E.
    Van Tinteren, H.
    Quispel-Janssen, J.
    Monkhorst, K.
    Burgers, S.
    Baas, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1746 - S1746
  • [5] Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/-UV1 telomerase vaccine
    Thunold, Solfrid
    Hernes, Eivor
    Farooqi, Saima
    Oejlert, asa Kristina
    Francis, Roslyn J.
    Nowak, Anna K.
    Szejniuk, Weronika Maria
    Nielsen, Soren Steen
    Cedres, Susana
    Perdigo, Marc Simo
    Sorensen, Jens Benn
    Meltzer, Carin
    Mikalsen, Lars Tore Gyland
    Helland, Aslaug
    Malinen, Eirik
    Haakensen, Vilde Drageset
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025, 52 (02) : 693 - 707
  • [6] First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
    Scherpereel, Arnaud
    Antonia, Scott
    Bautista, Yolanda
    Grossi, Francesco
    Kowalski, Dariusz
    Zalcman, Gerard
    Nowak, Anna K.
    Fujimoto, Nobukazu
    Peters, Solange
    Tsao, Anne S.
    Mansfield, Aaron S.
    Popat, Sanjay
    Sun, Xiaowu
    Lawrance, Rachael
    Zhang, Xiaoqing
    Daumont, Melinda J.
    Bennett, Bryan
    McKenna, Mike
    Baas, Paul
    LUNG CANCER, 2022, 167 : 8 - 16
  • [7] Follow-Up after First-Line Nivolumab Plus Ipilimumab in Patients with Pleural Mesothelioma: A Real-World Dutch Cohort Study (FLORA-Study)
    Douma, L. H.
    Hofman, M. M.
    Zwierenga, F.
    Buma, A. I. G.
    Schouwink, J. H.
    Burgers, J. A.
    Smesseim, I.
    Dumoulin, D. W.
    Aerts, J. G. J. V.
    de Gooijer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S71 - S71
  • [8] A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress
    Lam, Wei-Sen
    Lee, Y. C. Gary
    Creaney, Jenette
    Muruganandan, Sanjeevan
    Millward, Michael
    Read, Catherine
    Nowak, Anna
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1087 - S1087
  • [9] PHASE II STUDY OF CARBOPLATIN AND VINORELBINE 1ST LINE TREATMENT IN ADVANCED MALIGNANT PLEURAL MESOTHELIOMA
    Sorensen, Jens B.
    Bech, Cecilia
    Sorensen, Peter
    Frank, Hanna
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1354 - S1355
  • [10] Real-world safety and efficacy of nivolumab for ≥ 2nd line treatment of metastatic renal cell carcinoma: A retrospective cohort study in Croatia, Hungary, and Malta
    Vrdoljak, Eduard
    Magri, Claude
    Gamulin, Marija
    Boskovic, Lidija
    Omrcen, Tomislav
    Bajic, Zarko
    Dienes, Tamas
    Geczi, Lajos
    NEOPLASMA, 2021, 68 (01) : 208 - 215
123